Shin Nippon To Initiate Study For Zolmitriptan Migraine Nasal Spray
This article was originally published in PharmAsia News
Executive Summary
Shin Nippon Biomedical Laboratories plans to start a Phase I trial for anti-migraine nasal spray zolmitriptan in the U.S